{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T23:49:14Z","timestamp":1787701754485,"version":"build-2784847793"},"reference-count":33,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Chugai Pharmaceutical Co. Ltd."}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2022,1,11]]},"published-print":{"date-parts":[[2022,2]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>PD-L1 expression on tumor cells is a marker of PD-1\/PD-L1 antibody treatment efficacy for advanced non-small cell lung cancer (NSCLC). PD-L1 antibody (atezolizumab) prolongs overall survival (OS) compared with platinum doublet as first-line treatment for NSCLC with high PD-L1 expression. Bevacizumab enhanced cytotoxic agent and epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor efficacy in non-squamous (NS)-NSCLC, and PD-1\/PD-L1 antibodies in preclinical models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This single-arm phase II study investigated clinical benefits of adding bevacizumab 15\u2009mg\/kg to atezolizumab 1200\u2009mg fixed dose in a first-line setting for advanced NS-NSCLC patients with PD-L1 expression \u226550% without\n                      <jats:italic>EGFR<\/jats:italic>\n                      \/\n                      <jats:italic>ALK<\/jats:italic>\n                      \/\n                      <jats:italic>ROS1<\/jats:italic>\n                      alterations. Primary endpoint was objective response rate (ORR) assessed by central review committee. Secondary endpoints were progression-free survival (PFS), duration of response (DOR), OS, and safety.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 39 enrolled patients, 33 (84.6%) had stage IV NSCLC and 36 (92.3%) had smoking history. As of March 31, 2020, no patient had a complete response and 25 patients had a partial response (ORR=64.1%, 95% CI 47.18 to 78.80). Twelve-month PFS and OS rates were 54.9% (35.65 to 70.60) and 70.6% (50.53 to 83.74), respectively. The median DOR in 25 responders was 10.4 months (4.63\u2013not reached). The median treatment cycle was 12 (1 to 27). Nineteen patients discontinued study treatment because of disease progression (N=17) or immune-related adverse events (AEs) (N=2) (sclerosing cholangitis or encephalopathy). There were 23 serious AEs in 12 patients, but no grade 4\/5 toxicity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Atezolizumab with bevacizumab is a potential treatment for NS-NSCLC with high PD-L1 expression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>JapicCTI-184038.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2021-004025","type":"journal-article","created":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T12:04:21Z","timestamp":1643717061000},"page":"e004025","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":41,"title":["Phase II study of atezolizumab with bevacizumab for non-squamous non-small cell lung cancer with high PD-L1 expression (@Be Study)"],"prefix":"10.1136","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2960-4364","authenticated-orcid":false,"given":"Takashi","family":"Seto","sequence":"first","affiliation":[{"name":"Department of Thoracic Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaname","family":"Nosaki","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mototsugu","family":"Shimokawa","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Yamaguchi University Graduate School of Medicine, Ube, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Toyozawa","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunichi","family":"Sugawara","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine, Sendai Kousei Hospital, Sendai, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8787-5587","authenticated-orcid":false,"given":"Hidetoshi","family":"Hayashi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka-Sayama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruyasu","family":"Murakami","sequence":"additional","affiliation":[{"name":"Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5853-1424","authenticated-orcid":false,"given":"Terufumi","family":"Kato","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Kanagawa Cancer Center, Yokohama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiji","family":"Niho","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideo","family":"Saka","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, National Hospital Organization Nagoya Medical Center 4-1-1, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahide","family":"Oki","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, National Hospital Organization Nagoya Medical Center 4-1-1, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshige","family":"Yoshioka","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology, Kansai Medical University Hospital, Hirakata, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isamu","family":"Okamoto","sequence":"additional","affiliation":[{"name":"Research Institute for Diseases of the Chest, Kyushu University Hospital, Fukuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruko","family":"Daga","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Osaka City General Hospital, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Azuma","sequence":"additional","affiliation":[{"name":"Division of Respirology, Neurology, and Rheumatology, Department of Internal Medicine, Kurume University, Kurume, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Niigata Cancer Center Hospital, Niigata, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazumi","family":"Nishino","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology, Osaka International Cancer Institute, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rie","family":"Tohnai","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology, Hyogo Cancer Center, Akashi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyuki","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Internal Medicine III, Wakayama Medical University, Wakayama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiko","family":"Nakagawa","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka-Sayama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2022,2,1]]},"reference":[{"key":"2025100310453050000_10.2.e004025.1","doi-asserted-by":"publisher","DOI":"10.1038\/nature25183"},{"key":"2025100310453050000_10.2.e004025.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501824"},{"key":"2025100310453050000_10.2.e004025.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606774"},{"key":"2025100310453050000_10.2.e004025.4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32409-7"},{"key":"2025100310453050000_10.2.e004025.5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)00587-0"},{"key":"2025100310453050000_10.2.e004025.6","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1056\/NEJMoa1917346","article-title":"Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC","volume":"383","author":"Herbst","year":"2020","journal-title":"N Engl J Med"},{"key":"2025100310453050000_10.2.e004025.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801005"},{"key":"2025100310453050000_10.2.e004025.8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1810865"},{"key":"2025100310453050000_10.2.e004025.9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1716948"},{"key":"2025100310453050000_10.2.e004025.10","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30167-6"},{"key":"2025100310453050000_10.2.e004025.11","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.jtho.2020.11.025","article-title":"Atezolizumab plus chemotherapy for first-line treatment of non-squamous NSCLC: results from the randomized phase 3 IMpower132 trial","volume":"16","author":"Nishio","year":"2021","journal-title":"J Thorac Oncol"},{"key":"2025100310453050000_10.2.e004025.12","unstructured":"NCCN clinical practice guidelines in oncology, NCCN guideline non-small cell lung cancer, version 2, 2021. Available: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/nscl_blocks.pdf"},{"key":"2025100310453050000_10.2.e004025.13","unstructured":"Planchard D , Popat S , Kerr K . Metastatic non-small cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up, 2020. Available: https:\/\/www.esmo.org\/content\/download\/347819\/6934778\/1\/ESMO-CPG-mNSCLC-15SEPT2020.pdf [Accessed 2 June 2021]."},{"key":"2025100310453050000_10.2.e004025.14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa061884"},{"key":"2025100310453050000_10.2.e004025.15","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70381-X"},{"key":"2025100310453050000_10.2.e004025.16","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30634-5"},{"key":"2025100310453050000_10.2.e004025.17","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30035-X"},{"key":"2025100310453050000_10.2.e004025.18","doi-asserted-by":"publisher","DOI":"10.1038\/nm1699"},{"key":"2025100310453050000_10.2.e004025.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2013.07.012"},{"key":"2025100310453050000_10.2.e004025.20","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-12-4354"},{"key":"2025100310453050000_10.2.e004025.21","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3541"},{"key":"2025100310453050000_10.2.e004025.22","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2015.00202"},{"key":"2025100310453050000_10.2.e004025.23","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0053-3"},{"key":"2025100310453050000_10.2.e004025.24","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.cllc.2021.05.007","article-title":"Comparison of SP142 and 22C3 immunohistochemistry PD-L1 assays for clinical efficacy of atezolizumab in non-small cell lung cancer: results from the randomized oak trial","volume":"23","author":"Gadgeel","year":"2022","journal-title":"Clin Lung Cancer"},{"key":"2025100310453050000_10.2.e004025.25","doi-asserted-by":"crossref","first-page":"v460","DOI":"10.1093\/annonc\/mdx380.001","article-title":"Clinical efficacy of atezolizumab (Atezo) in PD-L1 subgroups defined by SP142 and 22C3 IHC assays in 2L+ NSCLC: results from the randomized oak study","volume":"28","author":"Gadgeel","year":"2017","journal-title":"Annals of Oncology"},{"key":"2025100310453050000_10.2.e004025.26","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01281-7"},{"key":"2025100310453050000_10.2.e004025.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.05.013"},{"key":"2025100310453050000_10.2.e004025.28","doi-asserted-by":"crossref","unstructured":"Brierley J , Gospodarowicz MK , Wittekind C . TNM classification of malignant tumours. In: Brierley J , Gospodarowicz MK , Wittekind C , eds. Lung. 8th edition. Hoboken, NJ: John Wiley & Sons, Inc, 2017: 106\u201312.","DOI":"10.1002\/9780471420194.tnmc21.pub3"},{"key":"2025100310453050000_10.2.e004025.29","doi-asserted-by":"crossref","unstructured":"Reck M , Rodr\u00edguez-Abreu D , Robinson AG . KEYNOTE-024: pembrolizumab (pembro) vs platinum-based chemotherapy (chemo) as first-line therapy for advanced NSCLC with a PD-L1 tumor proportion score (TPS) \u226550%. Presented at ESMO 2016, Copenhagen, Denmark, October 7-11 2016.","DOI":"10.1093\/annonc\/mdw435.40"},{"key":"2025100310453050000_10.2.e004025.30","doi-asserted-by":"crossref","unstructured":"Lopes G , YL W , Kudaba I . Pembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as first-line therapy for advanced\/metastatic NSCLC with a PD-L1 tumor proportion score (TPS) \u2265 1%: Open-label, phase 3 KEYNOTE-042 study. Presented at: 2018 ASCO Annual Meeting, Chicago, IL, June 1-5 2018.","DOI":"10.1200\/JCO.2018.36.18_suppl.LBA4"},{"key":"2025100310453050000_10.2.e004025.31","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S2213-2600(19)30084-0","article-title":"Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial","volume":"7","author":"Reck","year":"2019","journal-title":"Lancet Respir Med"},{"key":"2025100310453050000_10.2.e004025.32","unstructured":"EMA\/CHMP\/557479\/2019: International non-proprietary name: atezolizumab, Procedure No. EMEA\/H\/C\/004143\/II\/0019, 25 July 2019. Available: https:\/\/www.ema.europa.eu\/en\/documents\/variation-report\/tecentriq-h-c-004143-ii-0019-epar-assessment-report-variation_en.pdf [Accessed 2 Jun 2021]."},{"key":"2025100310453050000_10.2.e004025.33","doi-asserted-by":"publisher","DOI":"10.1080\/0284186X.2019.1598575"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2021-004025","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T17:45:44Z","timestamp":1759513544000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2021-004025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":33,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,2,1]]},"published-print":{"date-parts":[[2022,2]]}},"alternative-id":["10.1136\/jitc-2021-004025"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2021-004025","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2]]}}}